scholarly journals Statistical Methods for Quality Equivalence of Topical Products. 0.5 mg/g Betamethasone Ointment as a Case-Study

Pharmaceutics ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 318 ◽  
Author(s):  
Jordi Ocaña ◽  
Toni Monleón-Getino ◽  
Virginia Merino ◽  
Daniel Peris ◽  
Lluís Soler

This study examines the statistical implications, and their possible implementation, of the “Draft guideline on quality and equivalence of topical products” issued by the European Medicines Agency in 2018, with particular focus on the section devoted to quality equivalence of physical properties. A new confidence interval to conduct the quality equivalence test and a way to cope with the multiplicity of quality parameters are presented and discussed. As an example, the results and the statistical analysis of a study on betamethasone 0.5 mg/g ointment are presented. It is suggested that the equivalence limits proposed in the draft guideline are overly strict: It is as difficult to declare quality equivalence between two packaging formats of the same reference product as to declare quality equivalence between the reference and the test product.

Author(s):  
Yaqoob Iqbal Memon ◽  
Sundus Saeed Qureshi ◽  
Imdad Ali Kandhar ◽  
Naeem Ahmed Qureshi ◽  
Sumbul Saeed ◽  
...  

2019 ◽  
Vol 25 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Marjorie Argollo ◽  
Gionata Fiorino ◽  
Daniela Gilardi ◽  
Federica Furfaro ◽  
Giulia Roda ◽  
...  

Introduction: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Areas covered: In the next few years, also adalimumab biosimilars will become available for the treatment of inflammatory bowel disease (IBD). In fact, several of them (ABP501, BI 695501, GP2017, and SB5) have been approved by the European Medicines Agency (EMA) with the same indications of the reference product (Humira ®). Initial preclinical data proved a strong similarity between all biosimilars and the RP. Moreover, phase 3 studies in rheumatoid arthritis and psoriasis showed no differences in terms of efficacy, safety, and immunogenicity. Data on IBD patients are urgently needed. Expert opinion: Biosimilars of adalimumab showed equivalent clinical efficacy to the RP in other immunemediated diseases. However, defining the ideal patient’s profile to receive or to be switched to a biosimilar, choosing one biosimilar vs. another, or cross-switching among biosimilars, will become the next challenge in IBD.


2020 ◽  
Vol 21 (13) ◽  
pp. 1031-1039
Author(s):  
Suping Niu ◽  
Yan Li ◽  
Wenliang Dong ◽  
Lin Xia ◽  
Tiantian Shen ◽  
...  

Background: Desloratadine is a drug with a phenotypic polymorphism in metabolism and has been approved for use in many countries to treat allergic diseases. CYP2C8 and UGT2B10 are metabolic enzymes, which may be involved in the metabolism of desloratadine. Objective: This study aimed to demonstrate bioequivalence between the test product (desloratadine tablet) and the reference product AERIUS (5mg), both orally administered. And the role of UGT2B10 and CYP2C8 genotypes in healthy Chinese subjects with different Desloratadine metabolic phenotypes was examined. Methods: It was a randomized, open-label, and four-sequence, single-dose crossover study conducted on 56 healthy Chinese subjects. The pharmacokinetics (PK) and safety of the test and reference Desloratadine products were compared. UGT2B10 and CYP2C8 genotypes were determined by the TaqMan assay using genomic DNA. Multiple linear regression was applied to analyze the correlation between genotypes and the metabolic ratio. Results: The mean serum concentration-time curves of desloratadine and 3-OH-desloratadine were similar between the test product and the reference product. For the PK similarity comparison, the 90% CIs for the geometric mean ratios of Cmax, AUC0-t, and AUC0-∞ of desloratadine and 3-OH-desloratadine of test and reference product were completely within 80-125%. None of all 56 subjects had serious adverse events. Only 2 subjects were poor-metabolizers in 56 healthy subjects. There was no significant correlation between investigated genotypes of CYP2C8 and UGT2B10 and the metabolic ratio. Conclusion: The test desloratadine tablet was bioequivalent to the reference product. No direct relationship between CYP2C8 and UGT2B10 genotypes and desloratadine metabolic ratio was identified.


2020 ◽  
Author(s):  
Hideya Kawasaki ◽  
Hiromi Suzuki ◽  
Masato Maekawa ◽  
Takahiko Hariyama

BACKGROUND As pathogens such as influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can easily cause pandemics, rapid diagnostic tests are crucial for implementing efficient quarantine measures, providing effective treatments to patients, and preventing or containing a pandemic infection. Here, we developed the immunochromatography-NanoSuit® method, an improved immunochromatography method combined with a conventional scanning electron microscope (SEM), which enables observation of immunocomplexes labeled with a colloidal metal. OBJECTIVE A total of 197 clinical samples from patients suspected to be suffering from influenza were provided by a general hospital at the Hamamatsu University School of Medicine for examination using the Flu kit. METHODS Immunochromatography kit The ImunoAce® Flu kit (NP antigen detection), a human influenza commercial diagnosis kit, was purchased from TAUNS Laboratories, Inc. (Shizuoka, Japan). Au/Pt nanoparticles were utilized to visualize the positive lines. A total of 197 clinical samples from patients suspected to be suffering from influenza were provided by a general hospital at the Hamamatsu University School of Medicine for examination using the Flu kit. After macroscopic diagnosis using the Flu kit, the samples were stored in a biosafety box at room temperature (20-25 °C / 68 - 77 °F). The IgM detection immunochromatography kit against SARS-CoV-2 was obtained from Kurabo Industries, Ltd. (Osaka, Japan). One step rRT-PCR for influenza A rRT-PCR for influenza A was performed as described previously using Flu A universal primers. A Ct within 38.0 was considered as positive according to the CDC protocol. The primer/probe set targeted the human RNase P gene and served as an internal control for human nucleic acid as described previously. SEM image acquisition The immunochromatography kit was covered with a modified NanoSuit® solution based on previously published components (Nisshin EM Co., Ltd., Tokyo, Japan), placed first onto the wide stage of the specimen holder, and then placed in an Lv-SEM (TM4000Plus, Hitachi High-Technologies, Tokyo, Japan). Images were acquired using backscattered electron detectors with 10 or 15 kV at 30 Pa. Particle counting In fields containing fewer than 50 particles/field, the particles were counted manually. Otherwise, ImageJ/Fiji software was used for counting. ImageJ/Fiji uses comprehensive particle analysis algorithms that effectively count various particles. Images were then processed and counting was performed according to the protocol. Diagnosis and statistics The EM diagnosis and criteria for a positive test were defined as follows: particle numbers from 6 fields from the background area and test-line were statistically analyzed using the t-test. If there were more than 5 particles in one visual field and a significant difference (P < 0.01) was indicated by the t-test, the result was considered positive. Statistical analysis using the t-test was performed in Excel software. Statistical analysis of the assay sensitivity and specificity with a 95% confidence interval (95% CI) was performed using the MedCalc statistical website. The approximate line, correlation coefficient, and null hypothesis were calculated with Excel software. RESULTS Our new immunochromatography-NanoSuit® method suppresses cellulose deformity and makes it possible to easily focus and acquire high-resolution images of gold/platinum labeled immunocomplexes of viruses such as influenza A, without the need for conductive treatment as with conventional SEM. Electron microscopy (EM)-based diagnosis of influenza A exhibited 94% clinical sensitivity (29/31) (95% confidence interval [95%CI]: 78.58–99.21%) and 100% clinical specificity (95%CI: 97.80–100%). EM-based diagnosis was significantly more sensitive (71.2%) than macroscopic diagnosis (14.3%), especially in the lower influenza A-RNA copy number group. The detection ability of our method is comparable to that of real-time reverse transcription-polymerase chain reaction. CONCLUSIONS This simple and highly sensitive quantitative analysis method involving immunochromatography can be utilized to diagnose various infections in humans and livestock, including highly infectious diseases such as COVID-19.


Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 693
Author(s):  
Harald Walach ◽  
Rainer J. Klement ◽  
Wouter Aukema

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects. Result: The NNTV is between 200–700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer, while the NNTV to prevent one death is between 9000 and 50,000 (95% confidence interval), with 16,000 as a point estimate. The number of cases experiencing adverse reactions has been reported to be 700 per 100,000 vaccinations. Currently, we see 16 serious side effects per 100,000 vaccinations, and the number of fatal side effects is at 4.11/100,000 vaccinations. For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.


Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 48
Author(s):  
Ioana Gherghescu ◽  
M. Begoña Delgado-Charro

Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior to the regulatory approval. European Medicines Agency (EMEA, currently EMA) and Food and Drug Administration (FDA) repositories were searched to identify all biosimilar medicines approved before December 2019. Adalimumab biosimilars, and particularly their clinical evaluations, were used as a case study. In the past 13 years, the EMA has received 65 marketing authorization applications for biosimilar medicines with 55 approved biosimilars available in the EU market. Since the first biosimilar approval in 2015, the FDA has granted 26 approvals for biosimilars with only 11 being currently on the US market. Five adalimumab biosimilars have been approved in the EU and commercialized as eight different medicines through duplicate marketing authorizations. Whilst three of these are FDA-approved, the first adalimumab biosimilar will not be marketed in the US until 2023 due to Humira’s exclusivity period. The EU biosimilar market has developed faster than its US counterpart, as the latter is probably challenged by a series of patents and exclusivity periods protecting the bio-originator medicines, an issue addressed by the US’s latest ‘Biosimilar Action Plan’.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Muhammad Arif Budiyanto ◽  
Muhammad Hanzalah Huzaifi ◽  
Simon Juanda Sirait ◽  
Putu Hangga Nan Prayoga

AbstractSustainable development of container terminals is based on energy efficiency and reduction in CO2 emissions. This study estimated the energy consumption and CO2 emissions in container terminals according to their layouts. Energy consumption was calculated based on utility data as well as fuel and electricity consumptions for each container-handling equipment in the container terminal. CO2 emissions were estimated using movement modality based on the number of movements of and distance travelled by each container-handling equipment. A case study involving two types of container terminal layouts i.e. parallel and perpendicular layouts, was conducted. The contributions of each container-handling equipment to the energy consumption and CO2 emissions were estimated and evaluated using statistical analysis. The results of the case study indicated that on the CO2 emissions in parallel and perpendicular layouts were relatively similar (within the range of 16–19 kg/TEUs). These results indicate that both parallel and perpendicular layouts are suitable for future ports based on sustainable development. The results can also be used for future planning of operating patterns and layout selection in container terminals.


Sign in / Sign up

Export Citation Format

Share Document